Susquehanna Fundamental Investments LLC Trims Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Susquehanna Fundamental Investments LLC cut its stake in United Therapeutics Co. (NASDAQ:UTHR) by 0.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,235 shares of the biotechnology company’s stock after selling 470 shares during the period. Susquehanna Fundamental Investments LLC’s holdings in United Therapeutics were worth $17,277,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. ClariVest Asset Management LLC lifted its position in United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares during the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of United Therapeutics in the second quarter valued at about $30,000. Innealta Capital LLC purchased a new stake in shares of United Therapeutics in the second quarter valued at about $33,000. Rise Advisors LLC purchased a new stake in shares of United Therapeutics in the first quarter valued at about $32,000. Finally, Benjamin F. Edwards & Company Inc. raised its holdings in shares of United Therapeutics by 63.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 117 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $312.48, for a total transaction of $1,124,928.00. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $40,622.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $312.48, for a total transaction of $1,124,928.00. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $40,622.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO James Edgemond sold 7,785 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the transaction, the chief financial officer now directly owns 2,615 shares in the company, valued at approximately $947,597.55. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 111,252 shares of company stock valued at $36,939,427. Company insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on UTHR. Bank of America reduced their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 2nd. UBS Group upped their target price on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a report on Monday, July 8th. LADENBURG THALM/SH SH lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Wells Fargo & Company boosted their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $357.17.

United Therapeutics Stock Performance

Shares of UTHR opened at $358.53 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. The company has a market capitalization of $15.95 billion, a price-to-earnings ratio of 16.95, a PEG ratio of 1.29 and a beta of 0.57. The company’s 50 day simple moving average is $342.08 and its 200 day simple moving average is $295.35. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $366.08.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). The firm had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period in the previous year, the company posted $5.24 EPS. On average, sell-side analysts predict that United Therapeutics Co. will post 24.84 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.